ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

The purpose of this first-in-human study is to explore the safety, pharmacokinetics and effects of the study drug ADCX-020 in patients with advanced and metastatic solid tumors. ADCX-020 is an investigational anticancer therapy called antibody drug conjugate. This study is set up in multiple parts. In the first part of the study, participants receive increasing doses of ADCX-020. Then 2 or more doses will be assessed to identify the optimal dose. This optimal dose is subsequently evaluated for effect on different cancer types.

NCT Number	NCT07238075
Lead Sponsor	Adcytherix SAS
Conditions	Advanced Malignancy, Advanced Solid Cancers, Metastatic Solid Tumors
Enrollment	290 participants
Start Date	2026-02-23
Primary Completion	2029-07-31 (estimated)
Study Completion	2029-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-08